Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis

by Wai-kit Ming, Xiaoting Huang, Xiuhua Weng, Shen Lin, Yiwei Liu, Shaohong Luo, Hang Wang, Pinfang Huang
Published 2020-08-01